Cenexi turnaround delays
Cenexi's path to profitability may be delayed if new capacity ramp-up or commercial production timelines slip, or if lyophilizer issues recur.
GLAND / Q2-FY25 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. revenue stagnation
U.S. revenue has been flat for three quarters despite multiple launches; growth may not materialize as expected if new contracts or Saudi offtake are delayed.
Cenexi gross margin volatility
Cenexi gross margin fell sharply to 69% due to product mix; may not normalize quickly if site-level issues persist.
Biologics CDMO revenue uncertainty
Management declined to provide peak revenue potential for the Dr. Reddy's partnership, indicating early-stage and uncertain financial impact.